Y Intercept Hong Kong Ltd Buys 10,530 Shares of LivaNova PLC $LIVN

Y Intercept Hong Kong Ltd grew its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 43.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 34,568 shares of the company’s stock after purchasing an additional 10,530 shares during the period. Y Intercept Hong Kong Ltd’s holdings in LivaNova were worth $1,811,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in LIVN. Primecap Management Co. CA lifted its stake in shares of LivaNova by 0.7% during the 2nd quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock valued at $208,954,000 after buying an additional 32,942 shares in the last quarter. AQR Capital Management LLC grew its position in LivaNova by 30.5% in the second quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after acquiring an additional 478,525 shares in the last quarter. Geode Capital Management LLC raised its position in LivaNova by 1.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,429,740 shares of the company’s stock worth $64,374,000 after purchasing an additional 18,551 shares during the period. Artisan Partners Limited Partnership lifted its stake in shares of LivaNova by 112.9% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock valued at $56,167,000 after acquiring an additional 661,480 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after purchasing an additional 902,447 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research note on Monday, December 29th. Mizuho lifted their target price on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, December 16th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $66.00 price objective on shares of LivaNova in a research note on Friday, January 9th. Finally, Barclays upped their price objective on LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $69.38.

LivaNova Price Performance

NASDAQ:LIVN opened at $64.71 on Friday. The firm has a market cap of $3.53 billion, a price-to-earnings ratio of -16.18 and a beta of 0.97. LivaNova PLC has a one year low of $32.48 and a one year high of $65.57. The firm’s fifty day moving average is $62.88 and its two-hundred day moving average is $55.69. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.